Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. increased its holdings in shares of Cabaletta Bio, Inc. (NASDAQ:CABA) by 6.4% in the third quarter, Holdings Channel reports. The firm owned 125,845 shares of the company’s stock after buying an additional 7,518 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Cabaletta Bio were worth $594,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of CABA. HealthInvest Partners AB increased its position in shares of Cabaletta Bio by 162.0% during the third quarter. HealthInvest Partners AB now owns 168,522 shares of the company’s stock valued at $795,000 after acquiring an additional 104,201 shares during the last quarter. Intech Investment Management LLC acquired a new stake in Cabaletta Bio in the 3rd quarter valued at approximately $67,000. Jennison Associates LLC raised its position in Cabaletta Bio by 1.6% in the third quarter. Jennison Associates LLC now owns 5,632,681 shares of the company’s stock valued at $26,586,000 after purchasing an additional 86,214 shares during the period. GSA Capital Partners LLP acquired a new position in Cabaletta Bio during the third quarter worth $127,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Cabaletta Bio by 65.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,395 shares of the company’s stock worth $44,000 after buying an additional 3,724 shares during the period.

Analysts Set New Price Targets

Several research firms recently issued reports on CABA. UBS Group assumed coverage on Cabaletta Bio in a research note on Thursday, October 10th. They set a “buy” rating and a $10.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of Cabaletta Bio in a research note on Friday, November 15th. William Blair restated an “outperform” rating on shares of Cabaletta Bio in a report on Monday, November 18th. TD Cowen raised Cabaletta Bio to a “strong-buy” rating in a research report on Friday, November 29th. Finally, Wells Fargo & Company decreased their price objective on shares of Cabaletta Bio from $20.00 to $12.00 and set an “overweight” rating for the company in a research report on Friday, November 15th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $26.25.

Cabaletta Bio Stock Down 16.7 %

Shares of CABA stock opened at $2.29 on Thursday. The stock’s 50-day moving average price is $3.57 and its 200 day moving average price is $5.48. The stock has a market capitalization of $111.93 million, a PE ratio of -1.07 and a beta of 2.37. Cabaletta Bio, Inc. has a 52-week low of $1.76 and a 52-week high of $26.35.

Cabaletta Bio Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.